PsychiatryOnline CME -- Site Navigation

AJP CME Course for January 2008: Familial Risk Analyses of Attention Deficit Hyperactivity Disorder and Substance Use Disorders

Information to Participants

OBJECTIVES. After evaluating a specific journal article, participants should be able to demonstrate an increase in their knowledge of clinical medicine. Participants should be able to understand the contents of a selected research or review article and to apply the new findings to their clinical practice.

PARTICIPANTS. This program is designed for all psychiatrists in clinical practice, residents in Graduate Medical Education programs, medical students interested in psychiatry, and other physicians who wish to advance their current knowledge of clinical medicine.

EXPLANATION OF HOW PHYSICIANS CAN PARTICIPATE AND EARN CREDIT. In order to earn CME credit, subscribers should read through the material presented in the article. After reading the article, complete the CME quiz and submit your evaluation and study hours (up to 1 AMA PRA Category 1 Credit^TM).

CREDITS. The APA designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. The American Psychiatric Assocation (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Estimated Time to Complete Course: 1 hour
Begin date: January 1, 2008
End date: December 31, 2009

Information on Course

Title: Familial Risk Analyses of Attention Deficit Hyperactivity Disorder and Substance Use Disorders
Faculty: Joseph Biederman, M.D., Carter R. Petty, M.A., Timothy E. Wilens, M.D., Maria G. Fraire, B.A., Caitlin A. Purcell, B.A., Eric Mick, Sc.D., Michael C. Monuteaux, Sc.D., Stephen V. Faraone, Ph.D.
Affiliation: Department of Pediatric Psychopharmacology, Massachusetts General Hospital
Disclosures: Dr. Biederman has received research support from, has been a speaker for, or has been on the advisory boards for Shire, Eli Lilly, Pfizer, McNeil, Abbott, Neurosearch, Bristol-Myers Squibb, New River, Cephalon, Janssen, Novartis, UCB Pharma, Astra-Zeneca, Forest, Glaxo-Smith Kline, Neurosearch, the Stanley Medical Institute, the Lilly Foundation, the Prechter Foundation, NIMH, the National Institute of Child Health and Human Development, Cephalon, Novartis, and the National Institute on Drug Abuse. Dr. Wilens has received research support from, has been a speaker for, or has been on the advisory boards for Abbott, Ortho-McNeil, Eli Lilly, the National Institute on Drug Abuse, Neurosearch, Novartis, Shire, Glaxo-Smith Kline, and Pfizer. Dr. Eric Mick has received grant support from McNeil Pediatrics and NIMH and is a consultant for Janssen and Pfizer. Dr. Faraone has received research support from, has been a speaker for, or has been on the advisory boards for Eli Lilly, McNeil, Shire US, Novartis, Noven, Cephalon, NIMH, the National Institute of Child Health and Human Development, and the National Institute of Neurological Disorders and Stroke. The remaining authors report no competing interests.
Discussion of unapproved or investigational use of products*: None

*APA policy requires disclosure by CME authors of unapproved or investigational use of products discussed in CME programs. Off-label use of medications by individual physicians is permitted and common. Decisions about off-label use can be guided by scientific literature and clinical experience.

Take this course